Ayahuasca-inspired DMT/harmine formulation alters creative thinking dynamics during artistic creation
In a double‑blind, placebo‑controlled within‑subject study using an ecologically valid painting task, an ayahuasca‑inspired DMT/harmine formulation impaired convergent thinking (particularly in participants with higher baseline reasoning) and showed trend‑level reductions in divergent fluency and elaboration. At the process level both DMT/HAR and harmine reduced incubation‑related transitions, while DMT/HAR uniquely decreased transitions from incubation to illumination, indicating psychedelics alter the dynamic pathways to creative insight and that subjective altered meaning and insightfulness selectively predict divergent but not convergent outcomes.
Authors
- Milan Scheidegger
- Dominik Dornbierer
- Anne Aicher
Published
Abstract
Background
While psychedelics are often claimed to enhance creativity, their precise effects on distinct stages of creative cognition remain poorly understood. This study investigated the acute effects of an ayahuasca-inspired formulation combining N,N-dimethyltryptamine (DMT) and harmine (DMT/HAR), as well as harmine alone (HAR), on micro-level (divergent/convergent thinking) and macro-level (creative process dynamics) creativity.
Methods
In a double-blind, placebo-controlled, within-subject design, 30 healthy male participants completed three sessions (DMT/HAR, HAR, placebo). Micro-level creativity was assessed using the picture concept task (convergent thinking) and alternative uses task (divergent thinking). Macro-level dynamics were examined through a real-world painting task using the creative process report diary, which captured dynamic stage transitions. Subjective experiences were also recorded to explore their predictive value for creativity.
Results
DMT/HAR significantly impaired convergent thinking, particularly in individuals with higher baseline reasoning. Divergent thinking showed no overall effect but revealed trend-level reductions in fluency and elaboration under DMT/HAR. At the macro-level, both DMT/HAR and HAR reduced incubation-related transitions, while DMT/HAR uniquely decreased transitions from incubation to illumination, suggesting altered pathways to insight. Subjective experiences such as altered meaning perception and increased insightfulness selectively predicted divergent, but not convergent, thinking outcomes.
Conclusions
This study demonstrates that the effects of DMT/HAR on creativity are not uniform. By capturing real-world creative behavior through an ecologically valid painting task, this study offers the first evidence that psychedelics influence not only creative cognition but also the dynamic processes that give rise to it. These findings highlight the importance of integrating cognitive, phenomenological and process-level perspectives to better understand creative thinking under altered states. Future research should further investigate how individual differences in subjective experience and cognitive style modulate the unfolding of creative processes under psychedelics.
Research Summary of 'Ayahuasca-inspired DMT/harmine formulation alters creative thinking dynamics during artistic creation'
Introduction
Creativity is increasingly recognised as a crucial capacity for adaptability, innovation and problem solving, and impaired cognitive flexibility is implicated in several mental health conditions. Psychedelic drugs are hypothesised to promote cognitive flexibility and creative thinking, but empirical findings are mixed. Prior studies have reported enhancements, impairments or null effects on divergent and convergent thinking depending on drug type, dose, setting, timing of measurement and study design. The authors note a further gap: most laboratory studies assess creativity with isolated tasks rather than tracking how creative thinking unfolds over time during real-world creative work. To address this gap, Suay and colleagues examined acute effects of an ayahuasca-inspired pharmaceutical formulation combining N,N-dimethyltryptamine and harmine (DMT/HAR), harmine alone (HAR), and placebo, using a double-blind, placebo-controlled, within-subject design. They assessed micro-level creative cognition with standard tasks (convergent thinking via the picture concept task, and divergent thinking via the alternative uses task) and macro-level creative process dynamics during a 21-minute painting task using the creative process report diary (CRD) with experience sampling. The study also tested whether subjective altered-state experiences (measured with the 5D-ASC subscales) predicted changes in task-based creativity, aiming to integrate cognitive, phenomenological and process-level perspectives on psychedelic effects on creativity.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topic
- Authors
- APA Citation
Suay, D., Aicher, H. D., Singer, B., Mueller, M. J., Jelusic, A., Calzaferri, L., Springfeld, P., Dornbierer, D. A., & Scheidegger, M. (2025). Ayahuasca-inspired DMT/harmine formulation alters creative thinking dynamics during artistic creation. Journal of Psychopharmacology. https://doi.org/10.1177/02698811251353256
References (29)
Papers cited by this study that are also in Blossom
Aicher, H. D., Mueller, M. J., Dornbierer, D. A. et al. · Frontiers in Psychiatry (2024)
Baggot, M. J. · Preprints (2015)
Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Dornbierer, D. A., Marten, L., Mueller, J. et al. · Frontiers in Pharmacology (2023)
Dos Santos, R. G., Hallak, J. E. · Journal of Psychoactive Drugs (2016)
Girn, M., Mills, C., Roseman, L. et al. · NeuroImage (2020)
Hartogsohn, I. · Drug Science Policy and Law (2017)
Hartogsohn, I. · Frontiers in Human Neuroscience (2018)
Hendricks, P. S. · International Review of Psychiatry (2018)
Show all 29 referencesShow fewer
Krippner, S. · Journal of Psychoactive Drugs (1985)
Kuypers, K. P. C., Riba, &. J., De La Fuente Revenga, &. M. et al. · Psychopharmacology (2016)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. T. et al. · Translational Psychiatry (2021)
Mason, N. L., Mischler, E., Uthaug, M. V. et al. · Journal of Psychoactive Drugs (2019)
Mueller, J., Mueller, M. J., Aicher, H. D. et al. · International Journal of Neuropsychopharmacology (2025)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Prochazkova, L., Lippelt, D. P., Colzato, L. S. et al. · Psychopharmacology (2018)
Reiff, C. M., Richman, E. E., Nemeroff, C. B. et al. · American Journal of Psychiatry (2020)
Sessa, B. · Journal of Psychopharmacology (2008)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Timmermann, C., Roseman, L., Haridas, S. et al. · PNAS (2023)
Timmermann, C., Roseman, L., Schartner, M. et al. · Scientific Reports (2019)
Uthaug, M. V., Lancelotta, R., van Oorsouw, K. et al. · Psychopharmacology (2019)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Wießner, I., Falchi, M., Maia, L. O. et al. · Journal of Psychopharmacology (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.